News & Updates
Showing Multidisciplinary articles
Showing
Patients with IGT show poor response to lifestyle changes
A study of Thai patients with impaired glucose tolerance (IGT) has found only a slight reduction in weight among its participants, highlighting the need for more intensive efforts with structured lifestyle programs to prevent diabetes.
Obefazimod 50 mg for rheumatoid arthritis delivers in phase II trial
The investigational drug ABX464, also known as obefazimod, helps reduce disease activity in patients with rheumatoid arthritis (RA), according to the results of a phase II trial. The 50-mg dose is well tolerated, while the higher dose is associated with mild-to-moderate adverse effects resulting in treatment discontinuation.
Novel PDE4 inhibitor slows IPF progression
Treatment with BI 1015550, a novel investigational phosphodiesterase 4 (PDE4) inhibitor, slows lung function decline in patients with idiopathic pulmonary fibrosis (IPF) with or without background antifibrotic therapy, according to a 12-week phase II trial data presented at ATS 2022.
Women with rheumatic diseases face adverse pregnancy outcomes
Pregnancies in women with rheumatic and systemic autoimmune diseases—including systemic lupus erythematosus, spondyloarthritis, and rheumatoid arthritis—pose significant health risks and are likely to lead to unfavourable outcomes, according to several studies presented at this year’s European Alliance of Associations for Rheumatology (EULAR) Congress.
